The longitudinal trends in the relationship between drug-induced extrapyramidal symptoms and personal and social performance in a population of the patients with schizophrenia: A latent growth model

[1]  Y. Ahn,et al.  Refinement of the SWN-20 based on the Rasch rating model. , 2015, Comprehensive psychiatry.

[2]  L. Pani,et al.  Towards a framework for treatment effectiveness in schizophrenia , 2014, Neuropsychiatric disease and treatment.

[3]  E. Alexopoulos,et al.  Correlation between the Personal and Social Performance scale (PSP) and the Positive and Negative Syndrome Scale (PANSS) in a Greek sample of patients with schizophrenia , 2014, BMC Psychiatry.

[4]  Shin-Min Lee,et al.  Validation of the Taiwanese Mandarin version of the Personal and Social Performance scale in a sample of 655 stable schizophrenic patients , 2013, Schizophrenia Research.

[5]  Se-Won Lim,et al.  Effectiveness of paliperidone extended‐release for patients with schizophrenia: focus on subjective improvement , 2013, Human psychopharmacology.

[6]  D. Stull,et al.  Reliability and validity of the Personal and Social Performance scale in patients with schizophrenia , 2012, Schizophrenia Research.

[7]  Sung-Wan Kim,et al.  The effect of paliperidone extended release on subjective well-being and responses in patients with schizophrenia , 2012, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[8]  Yeni Kim,et al.  Exploration of the associations between neurocognitive function and neuroleptics side effects. , 2012, Journal of psychiatric research.

[9]  Z. Weihua,et al.  The Chinese version of the Personal and Social Performance Scale (PSP): Validity and reliability , 2011, Psychiatry Research.

[10]  J. Chang,et al.  The usefulness of a self-report questionnaire measuring auditory verbal hallucinations , 2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[11]  Yeni Kim,et al.  Clinician-rated functioning and patient-rated quality of life in schizophrenia: Implications of their correspondence for psychopathology and side effects , 2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[12]  P. Jansen,et al.  Systematic Evaluation of Rating Scales for Drug-Induced Parkinsonism and Recommendations for Future Research , 2010, Journal of clinical psychopharmacology.

[13]  Seong-Jin Cho,et al.  The model of the relationships among the predictors of quality of life in chronic stage of schizophrenia , 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[14]  P. Bebbington,et al.  Side‐effects of antipsychotic medication and health‐related quality of life in schizophrenia , 2009, Acta psychiatrica Scandinavica. Supplementum.

[15]  D. Patrick,et al.  Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia , 2009 .

[16]  H. Nasrallah,et al.  Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia , 2008, Psychiatry Research.

[17]  G. Juckel,et al.  The new approach: psychosocial functioning as a necessary outcome criterion for therapeutic success in schizophrenia , 2008, Current opinion in psychiatry.

[18]  D. Revicki,et al.  Psychometric properties of the Personal and Social Performance scale (PSP) among individuals with schizophrenia living in the community , 2008, Quality of Life Research.

[19]  Y. Kaneda,et al.  Predictors of subjective and objective quality of life in outpatients with schizophrenia , 2008, Psychiatry and clinical neurosciences.

[20]  T. Burns,et al.  Social functioning as an outcome measure in schizophrenia studies , 2007, Acta psychiatrica Scandinavica.

[21]  P. Haddad,et al.  Adverse effects of antipsychotics as outcome measures , 2007, British Journal of Psychiatry.

[22]  J. Bobes,et al.  Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: Results of the CLAMORS Study , 2007, Schizophrenia Research.

[23]  Y. Kaneda,et al.  Effect of antipsychotic replacement with quetiapine on the symptoms and quality of life of schizophrenic patients with extrapyramidal symptoms , 2006, Human psychopharmacology.

[24]  Y. Ahn,et al.  Subjective response to clozapine and risperidone treatment in outpatients with schizophrenia , 2006, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[25]  Terry E. Duncan,et al.  Alcohol use from ages 9 to 16: A cohort-sequential latent growth model. , 2006, Drug and alcohol dependence.

[26]  N. Oldridge,et al.  Psychometric Properties of an Established Heart Disease Specific Health-related Quality of Life Questionnaire for Pacemaker Patients , 2005, Quality of Life Research.

[27]  M. Lambert,et al.  Randomized double blind comparison of olanzapine vs. clozapine on subjective well‐being and clinical outcome in patients with schizophrenia , 2005, Acta psychiatrica Scandinavica.

[28]  Peter B. Jones,et al.  The Clinical Global Impression–Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia , 2003, Acta psychiatrica Scandinavica. Supplementum.

[29]  Y. Kaneda,et al.  Schizophrenia Quality of Life Scale: validation of the Japanese version , 2002, Psychiatry Research.

[30]  Y. Ahn,et al.  Subjective emotional experience and cognitive impairment in drug-induced akathisia. , 2002, Comprehensive psychiatry.

[31]  Toshiya Inada,et al.  Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol , 2002, Schizophrenia Research.

[32]  D. Naber,et al.  Subjective well-being and quality of life under atypical antipsychotic treatment , 2002, Psychopharmacology.

[33]  R. P. McDonald,et al.  Principles and practice in reporting structural equation analyses. , 2002, Psychological methods.

[34]  H. Rüdiger,et al.  Improvement of schizophrenic patients’ subjective well-being under atypical antipsychotic drugs , 2001, Schizophrenia Research.

[35]  G. A. Marcoulides,et al.  New developments and techniques in structural equation modeling , 2001 .

[36]  P. Morosini,et al.  Development, reliability and acceptability of a new version of the DSM‐IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social funtioning , 2000, Acta psychiatrica Scandinavica.

[37]  D. Revicki,et al.  Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: Quality of life and clinical outcomes of a randomized clinical trial , 1999, Quality of Life Research.

[38]  J. Gerlach,et al.  Subjective experience of treatment, side‐effects, mental state and quality of life in chronic schizophrenic out‐patients treated with depot neuroleptics , 1996, Acta psychiatrica Scandinavica.

[39]  T. Barnes.  A Rating Scale for Drug-Induced Akathisia , 1989, British Journal of Psychiatry.

[40]  M. Krawiecka,et al.  A standardized psychiatric assessment scale for rating chronic psychotic patients , 1977, Acta psychiatrica Scandinavica.

[41]  G. Simpson,et al.  A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS , 1970, Acta psychiatrica Scandinavica. Supplementum.

[42]  이현정,et al.  Tolerability, Safety and Effectiveness of Paliperidone ER in Patients with Schizophrenia : A 24-Week Interim Analysis of the 48-Week Open-Label, Prospective, Switch Study , 2013 .

[43]  J. Bobes,et al.  Validation of the Spanish Personal and Social Performance scale (PSP) in outpatients with stable and unstable schizophrenia. , 2011 .

[44]  J. Bobes,et al.  Validación de la versión española de la escala de Funcionamiento Personal y Social en pacientes ambulatorios con esquizofrenia estable o inestable , 2011 .

[45]  W. Marks.  Deep Brain Stimulation Management: Abnormal Involuntary Movement Scale , 2010 .

[46]  稲田 俊也.  DIEPSS : a second-generation rating scale for antipsychotic-induced extrapyramidal symptoms : drug-induced extrapyramidal symptoms scale , 2009 .

[47]  R. Heslegrave,et al.  A conceptual model of quality of life in schizophrenia: Description and preliminary clinical validation , 2004, Quality of Life Research.

[48]  J. Mcardle,et al.  Advanced studies of individual differences linear dynamic models for longitudinal data analysis. , 2001 .